Charles Homcy, M.D.

Dr. Charles Homcy joined Third Rock Ventures, a venture capital firm, in 2010 and currently serves on the scientific advisory board. He has served as a member of the BridgeBio board of directors since 2018, as chairman of pharmaceuticals since 2019, and as lead director since 2020.

Previously, Dr. Homcy served as president and CEO of Portola Pharmaceuticals, a clinical biotechnology company, since co-founding the company in 2003 until 2010. Prior to that, Dr. Homcy served as the president of research and development at Millennium Pharmaceuticals, Inc. (currently, Takeda Oncology), a biopharmaceutical company, following its acquisition of COR Therapeutics, Inc. in 2002. He joined COR Therapeutics, a biopharmaceutical company, in 1995 as executive vice president of research and development, and he served as a director of the company from 1998 to 2002.

Dr. Homcy was a clinical professor of medicine at the University of California, San Francisco Medical School, and attending physician at the San Francisco Veterans Affairs Hospital from 1997 to 2011. He was previously president of the medical research division of American Cyanamid-Lederle Laboratories, a division of Wyeth-Ayerst Laboratories. He currently serves on the board of directors of Maze Therapeutics, a biopharmaceutical company, and was formerly a director of Portola Pharmaceuticals from 2004 until 2019, and Global Blood Therapeutics from 2012 until 2019.

Dr. Homcy holds a B.A. and an M.D. from Johns Hopkins University and currently serves on its board of trustees.